Froechlich, Guendalina Gentile, Chiara Infante, Luigia Caiazza, Carmen Pagano, Pasqualina Scatigna, Sarah Cotugno, Gabriella D'Alise, Anna Morena Lahm, Armin Scarselli, Elisa
...
Published in
International journal of molecular sciences
HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast cancer. Its recent identification as a marker of some triple-negative breast tumors renders it an attractive target, presently investigate...
Sagara, Miyako Miyamoto, Shohei Itoh, Shun Soda, Yasushi Tani, Kenzaburo
Published in
Anticancer research
Breast cancer is the most common cancer in women worldwide, and triple-negative breast cancer (TNBC) is highly refractory to current standard therapies. Oncolytic virotherapy has recently gathered attention as a new treatment candidate for refractory cancers. We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers,...
Burman, Bharat Pesci, Giulio Zamarin, Dmitriy
Published in
Cancers
Preclinical and clinical studies dating back to the 1950s have demonstrated that Newcastle disease virus (NDV) has oncolytic properties and can potently stimulate antitumor immune responses. NDV selectively infects, replicates within, and lyses cancer cells by exploiting defective antiviral defenses in cancer cells. Inflammation within the tumor mi...
Koch, Marilin S Lawler, Sean E Chiocca, E Antonio
Published in
Cancers
Herpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of oncology indications. Successful clinical data resul...
Menotti, Laura Avitabile, Elisa
Published in
International journal of molecular sciences
Oncolytic viruses are smart therapeutics against cancer due to their potential to replicate and produce the needed therapeutic dose in the tumor, and to their ability to self-exhaust upon tumor clearance. Oncolytic virotherapy strategies based on the herpes simplex virus are reaching their thirties, and a wide variety of approaches has been envisio...
Georgi, Fanny Andriasyan, Vardan Witte, Robert Murer, Luca Hemmi, Silvio Yu, Lisa Grove, Melanie Meili, Nicole Kuttler, Fabien Yakimovich, Artur
...
Published in
Antimicrobial Agents and Chemotherapy
Adenoviruses (AdVs) are prevalent and give rise to chronic and recurrent disease. Human AdV (HAdV) species B and C, such as HAdV-C2, -C5, and -B14, cause respiratory disease and constitute a health threat for immunocompromised individuals. HAdV-Cs are well known for lysing cells owing to the E3 CR1-β-encoded adenovirus death protein (ADP). We previ...
Oh, Chang-Myung Chon, Hong Jae Kim, Chan
Published in
International Journal of Molecular Sciences
Oncolytic virus (OV) is a new therapeutic strategy for cancer treatment. OVs can selectively infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Moreover, they can remodel the tumor microenvironment toward a T cell-inflamed phenotype by stimulating widespread host immune responses ag...
Rius-Rocabert, Sergio García-Romero, Noemí García, Antonia Ayuso-Sacido, Angel Nistal-Villan, Estanislao
Published in
International Journal of Molecular Sciences
Glioma tumors are one of the most devastating cancer types. Glioblastoma is the most advanced stage with the worst prognosis. Current therapies are still unable to provide an effective cure. Recent advances in oncolytic immunotherapy have generated great expectations in the cancer therapy field. The use of oncolytic viruses (OVs) in cancer treatmen...
Yoon, A-Rum Jung, Bo-Kyeong Choi, Eunyoung Chung, Eugene Hong, JinWoo Kim, Jin-Soo Koo, Taeyoung Yun, Chae-Ok
Published in
Molecular therapy : the journal of the American Society of Gene Therapy
CRISPR-Cas12a represents a class 2/type V CRISPR RNA-guided endonuclease, holding promise as a precise genome-editing tool in vitro and in vivo. For efficient delivery of the CRISPR-Cas system into cancer, oncolytic adenovirus (oAd) has been recognized as a promising alternative vehicle to conventional cancer therapy, owing to its cancer specificit...
Krutzke, Lea Allmendinger, Ellen Hirt, Katja Kochanek, Stefan
Published in
Human Gene Therapy
Oncolytic viruses are promising anticancer agents; however, regarding their clinical efficacy, there is still significant scope for improvement. Preclinical in vivo evaluation of oncolytic viruses is mainly based on syngeneic or xenograft tumor models in mice, which is labor-intensive and time-consuming. Currently, a large proportion of development...
